<?xml version="1.0" encoding="UTF-8"?>
<p>An improved form of PolyI:PolyC, the drug Ampligen, is currently at the stage of clinical trials. Ampligen (PolyI:PolyC
 <sub>12</sub>U) is a double-stranded complex of polyriboinosinic acid and a copolymer of cytidyl and uridylic acids (with a C : U ratio of 12 : 1) and a length from 500 bp to 2000 bp (Hemispherx Biopharma, Inc., USA) [
 <xref ref-type="bibr" rid="CR75">75</xref>]. It is an IFN inducer with a markedly reduced incidence of adverse effects as compared to the parent compound. In the ClinicalTrials.gov Database, 16 types of clinical trials of this drug are registered. The effectiveness of the drug Ampligen has been demonstrated in the framework of combination therapy of chronic fatigue syndrome and acquired immunodeficiency syndrome (AIDS). Currently, the drug has been approved in Argentina for the treatment of severe cases of myalgic encephalomyelitis/chronic fatigue syndrome [
 <xref ref-type="bibr" rid="CR76">76</xref>].
</p>
